NEW YORK (GenomeWeb) – Rosetta Genomics reported after the close of the market on Wednesday a sharp increase in its revenues for the first half of 2014.

For the six months ended June 30, the miRNA-based molecular diagnostics firm posted $553,779 in revenues, up from $193,012 in the first half of 2013. The company attributed the uptick to growing awareness of and demand for the Rosetta Cancer Origin Test but did not provide details.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

NPR reports that Turkish high school students will no longer study evolution.

Researchers report they sequenced and identified plant species in an "al fresco" laboratory.

An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.

In PNAS this week: host contributors to typhoid fever risk, effects of obesity-related variants near TMEM18, and more.